Published: Apr 2016
ACE Report #8932
Ace Report Cover Metabolic Disorders

WCO-IOF 2016: Denosumab versus zoledronic acid following oral bisphosphonate therapy

Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A

A randomized double-blind study of denosumab (DMAB) compared with zoledronic acid (ZOL) in postmenopausal women with osteoporosis previously treated with oral bisphosphonates

Contributing Authors: P Miller N Pannacciulli JP Brown E Czerwinski BS Nedergaard MA Bolognese J Malouf HG Bone JY Reginster A Singer C Wang RB Wagman SR Cummings

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.